ÂÜÀòÂÒÂ×

Dr. Gillian Payne joined Carbon in 2022 to lead the Analytical Sciences group which develops analytics and critical reagents/reference standards in support of early stage development and CMC release and characterization assays, comparability studies, and process characterization. Dr. Payne has over 25 years of experience in various roles including CMC analytics, clinical bioanalytics/biomarker, and discovery research for early and late-stage programs in disease indications that include cancer, hemoglobinopathies and metabolic diseases. Dr. Payne has worked in the fields of apoptosis technology and antibody drug conjugates (ADCs) to treat cancer, cell and gene therapy (CAR Ts and stem cells with LVV gene delivery and CRISPR/Cas9 edited/AVV gene delivery) at ImmunoGen Inc., bluebird bio and CRISPR Therapeutics.

She earned her B.A. in chemistry and B.Mus. in piano performance at Oberlin College and Conservatory and Ph.D. in Biochemistry at the University of North Carolina-Chapel Hill in the laboratory of Nobel Prize recipient, Professor Aziz Sancar. She completed postdoctoral studies at Harvard Medical School in the laboratory of Professor Christopher T Walsh.